Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon to Adopt IFRS
May 30, 2017
- Bayer Fails to Report 12 Side Effect Cases for Xarelto, Scandal Probe Finds
May 29, 2017
- Zytiga Filed for Earlier Prostate Cancer Treatment
May 29, 2017
- FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
- Teijin Pharma Licenses Tau-Targeting Alzheimer’s Drug to Merck
May 29, 2017
- Over 50% of Doctors Don’t Allow Gx Switches for Certain Products: Survey
May 26, 2017
- TS-1 Generics Now Have Same Indications as Originator
May 25, 2017
- Sensor-Embedded Abilify Resubmitted to FDA
May 25, 2017
- Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
- FY2016 Sales Dip for 27 Japan Makers, Second-Tier/Mid-Sized Firms Fare Well: Jiho Tally
May 24, 2017
- 4 Major Distributors’ Wholesale Biz Sinks on Hep C Pullback, Price Revision
May 23, 2017
- Lantus XR Shows Efficacy in Japan Outcome Study: Interim Report
May 23, 2017
- EMA Accepts Application for Fujifilm Kyowa Kirin’s Humira Biosimilar
May 23, 2017
- Ethical Drug Sales Down 4.4% in March: Crecon
May 22, 2017
- Japan NDA Filed for Januvia-Suglat Combination
May 22, 2017
- MHLW OKs Xalkori for ROS1-Positive NSCLC; Zosyn, Kyprolis for Add’l Use
May 19, 2017
- Ogeda Acquisition Completed: Astellas
May 18, 2017
- Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
May 17, 2017
- Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
- Otsuka Gets Japan Rights to Teva’s Migraine Med
May 16, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…